The Pharma AI Monitoring Playbook: Track LLM Mentions, Catch Hallucinations, Protect Your Brand
Most pharmaceutical companies still don’t know what ChatGPT says about their drugs. They don’t know whether Perplexity recommends their biologic […]
How Pharma Teams Turn AI Drug Mentions Into Strategic Intelligence
Every day, millions of patients type questions about their prescriptions into ChatGPT, Gemini, Claude, and Perplexity. They ask whether Ozempic
Detect AI Drug Misinformation Before It Hits Patients: A Pharma Playbook
At some point in the last eighteen months, the drug information environment crossed a threshold. Patients stopped asking Google first.
What Patients Ask AI About Drugs That They Never Ask Doctors
There’s a question a patient on Ozempic typed into ChatGPT last year that she hadn’t mentioned to her endocrinologist in
AI Monitoring for Medical Affairs: What to Track Before the FDA Does
When a patient asks ChatGPT whether they can take Ozempic while on metformin, that answer — accurate or not —
AI Search Is Rewriting the Patient Journey — And Most Pharma Teams Haven’t Noticed
For two decades, pharmaceutical commercial teams built their patient journey models around a predictable sequence: symptom onset, physician visit, diagnosis,
AI Gets Oncology Drugs Wrong: What Pharma Brand Teams Must Track Now
Ask ChatGPT whether pembrolizumab is approved for small cell lung cancer. The answer you get depends on which version you
When AI Prescribes Trouble: The Legal Ambiguity Pharma Can’t Ignore
ChatGPT, Gemini, and Claude are answering drug questions millions of times a day. Some of those answers are wrong. Here
Pharma’s New Channel Problem: How AI Assistants Are Reshaping Drug Brand Visibility, Patient Safety, and Regulatory Risk
When a patient types “What’s the difference between Ozempic and Mounjaro?” into ChatGPT, no medical affairs team reviews the answer
AI Doesn’t Read Drug Labels Like Humans Do — And Pharma Is Paying the Price
When a patient types “can I take Ozempic with metformin” into ChatGPT, they are not reading an FDA-approved label. They
Catch It Before It Escalates: How to Monitor AI Mentions of Your Drug for Early Safety Signals
In February 2023, a wave of posts began appearing on Reddit’s r/antidepressants forum describing a specific withdrawal effect from a
Biosimilar AI Monitoring: The $100B Battle Playing Out in ChatGPT Right Now
Amgen’s Hadlima launched in the United States in July 2023. AbbVie’s Humira had dominated adalimumab prescribing for two decades. The
